1
|
Smith J, Aloudat T. Dilemmas in access to medicines: a humanitarian perspective. Lancet 2017; 389:1007-1008. [PMID: 28290989 DOI: 10.1016/s0140-6736(17)30660-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Accepted: 12/13/2016] [Indexed: 11/18/2022]
Affiliation(s)
- James Smith
- Médecins sans Frontières, 78 Rue de Lausanne, Geneva 1211, Switzerland.
| | - Tammam Aloudat
- Médecins sans Frontières, 78 Rue de Lausanne, Geneva 1211, Switzerland
| |
Collapse
|
2
|
Abstract
One-third of the world's population lacks access to the most basic essential drugs. For the destitute sick in the developing world, the price of medicines can determine whether they will be treated. Patents drive drug prices up, the resultant monopoly status allowing the producer to charge whatever price the market will bear. The World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which provides 20 years' patent protection for pharmaceuticals, also includes safeguards such as compulsory licensing, to ensure that countries can override patents whenever they are a barrier to access to medicines. Intense lobbying from the multinational pharmaceutical industry and some Western governments, however, has frustrated the use of these safeguards. Experience from South Africa, Thailand, Kenya and Guatemala shows the enormous pressures countries face in implementing the TRIPS Agreement in a manner that protects public health and underscores the vital role played by civil society in defending the right to access affordable medicines.
Collapse
|
3
|
Reddock J. Eastern Caribbean Physicians' Responses to Providing HIV/AIDS Care in Resource-Limited Settings: We've Come a Long Way, but We're Not There Yet. J Int Assoc Provid AIDS Care 2014; 15:370-9. [PMID: 24729071 DOI: 10.1177/2325957414525755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Physicians' ability to provide care to patients living with HIV/AIDS (PLWHA) in the Eastern Caribbean is influenced by economic constraints, sociocultural norms that govern interpersonal interactions, and the pervasive stigma linked to the disease. Although the economic environment determines national capacity to acquire various treatment and monitoring technologies, Eastern Caribbean physicians respond to practicing in a resource-limited setting by making choices that are influenced by the collectivist ethos that governs interpersonal relationships. Through qualitative interviews, the study finds that the social stigma associated with the disease requires physicians to "go the extra mile" to provide care in ways that allow PLWHA to protect their privacy in small, closely networked societies.
Collapse
|
4
|
Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, du Cros P. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012; 54:1465-72. [PMID: 22431808 DOI: 10.1093/cid/cis227] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The need to improve access to care and treatment for chronic hepatitis C virus (HCV) infection in resource-limited settings is receiving increasing attention. Key priorities for scaling up HCV treatment and care include reducing the cost of current and future treatment; simplifying the package of care; identifying opportunities to shift specific tasks to nonspecialists to overcome human resource constraints; service integration with human immunodeficiency virus (HIV) clinics, prison health services, and needle syringe and oral substitution therapy programs; improving surveillance, monitoring, and research; encouraging patient and community engagement; focusing specifically on the needs of vulnerable groups; and increasing financial and political commitment. Many of these obstacles have been addressed in rolling out treatment for human immunodeficiency virus during the last decade, and a number of lessons can be drawn to help improve access to HCV care.
Collapse
Affiliation(s)
- Nathan Ford
- Médecins Sans Frontières, Geneva, Switzerland.
| | | | | | | | | | | | | |
Collapse
|
5
|
Von Schoen-Angerer T, Ford N, Arkinstall J. Access to Medicines in Resource-limited Settings: The End of a Golden Decade? Glob Adv Health Med 2012. [PMCID: PMC3833470 DOI: 10.7453/gahmj.2012.1.1.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Strong international mobilization and political will drove a golden decade for global health. Key initiatives over the last decade include setting of health-related Millennium Development Goals; the Commission on Macroeconomics and Health; the creation of the Global Fund to Fight AIDS, Tuberculosis and Malaria; the Doha Declaration on the TRIPS Agreement and Public Health affirming countries' rights to protect public health when implementing patent rules; and the creation of product development partnerships to address neglected areas of research and development. Significant progress was made in reducing the incidence of and morbidity and mortality from human immunodeficiency virus (HIV), tuberculosis (TB), and malaria, with a major impact made through increased access to medicines. Antiretroviral treatment for HIV was expanded to 6.6 million people, and medication prices were reduced significantly through generic competition. However, donor support has started to decline at a time when many patients still wait for treatment and the prices of needed newer medicines are on the increase due to patent protection. TB incidence has started to decrease, but progress in diagnosis and treatment of multi-drug-resistant TB has been slow due to complexity of treatment and high drug costs. Promising new TB drugs in development need to be introduced rapidly and appropriately while treatment is being expanded. The introduction of more affordable artemisinin combination therapies for malaria contributed to significantly reducing malaria incidence and mortality, but challenges remain in ensuring that the latest recommendations for treating severe malaria are implemented. Looking to the next decade, there is a worrisome mismatch between additional health priorities accompanied by shifting burdens of disease that need to be addressed and dwindling political attention and financial support. Difficulties in producing and guaranteeing access to affordable medicines are expected from a changing pharmaceutical market where an appropriate balance between trade and health has not been found. Systematic changes through a global framework for research and development and access are needed to support increased innovation and access to the health tools of the next decade.
Collapse
Affiliation(s)
| | - Nathan Ford
- Médecins Sans Frontières Access Campaign and a research associate at the Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa
| | | |
Collapse
|
6
|
Ford N, Calmy A, Mills EJ. The first decade of antiretroviral therapy in Africa. Global Health 2011; 7:33. [PMID: 21958478 PMCID: PMC3192657 DOI: 10.1186/1744-8603-7-33] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2011] [Accepted: 09/29/2011] [Indexed: 11/10/2022] Open
Abstract
The past decade has seen remarkable progress in increasing access to antiretroviral therapy in resource-limited settings. Early concerns about the cost and complexity of treatment were overcome thanks to the efforts of a global coalition of health providers, activists, academics, and people living with HIV/AIDS, who argued that every effort must be made to ensure access to essential care when millions of lives depended on it. The high cost of treatment was reduced through advocacy to promote access to generic drugs; care provision was simplified through a public health approach to treatment provision; the lack of human resources was overcome through task-shifting to support the provision of care by non-physicians; and access was expanded through the development of models of care that could work at the primary care level. The challenge for the next decade is to further increase access to treatment and support sustained care for those on treatment, while at the same time ensuring that the package of care is continuously improved such that all patients can benefit from the latest improvements in drug development, clinical science, and public health.
Collapse
Affiliation(s)
- Nathan Ford
- Médecins Sans Frontières, Geneva, Switzerland.
| | | | | |
Collapse
|
7
|
Patrick PA, Jibilian A, Herasme O, Valencia J, Hernandez EC, Jurado S, Aguais J. The Efficacy of a US-Based Medicine Recycling Program Delivering Antiretroviral Drugs Worldwide. ACTA ACUST UNITED AC 2009; 8:25-9. [DOI: 10.1177/1545109708326665] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Since 1996, AID FOR AIDS International (AFAI) has collected unused antiretroviral drugs (ART) and ``recycled'' these medications to over 600 people living with human immunodeficiency virus/AIDS abroad under its AIDS Treatment Access Program. The investigators evaluated AIDS Treatment Access Program's efficacy using immunologic and virologic outcomes. Of the 404 eligible clients who had baseline and follow-up CD4 counts, mean baseline versus most recent measure was 230 + 222 cells/mm 3 versus 372 + 256 cells/mm3 (P < .01). Of the 216 eligible clients who had baseline (>400 copies/mL) and follow-up viral loads, 62% (134/ 216) had undetectable viral loads (<400 copies/mL) at their most recent measure. Median enrollment time in the recycling program was 3.1 years (range: 6 months to 9.5 years). AFAI's medication recycling program is efficacious in reaching and improving the clinical outcomes of people living with HIV/AIDS (PLWHA). Such programs should be considered a viable option among scale-up programs until governments provide universal access of ART to PLWHA.
Collapse
Affiliation(s)
- Patricia A. Patrick
- Winthrop-University Hospital, Mineola, New York, , School of Public Health, New York Medical College, Valhalla, New York
| | | | - Omarys Herasme
- School of Public Health, New York Medical College, Valhalla, New York
| | | | | | | | | |
Collapse
|
8
|
Yu D, Souteyrand Y, Banda MA, Kaufman J, Perriëns JH. Investment in HIV/AIDS programs: does it help strengthen health systems in developing countries? Global Health 2008; 4:8. [PMID: 18796148 PMCID: PMC2556650 DOI: 10.1186/1744-8603-4-8] [Citation(s) in RCA: 99] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2008] [Accepted: 09/16/2008] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND There is increasing debate about whether the scaled-up investment in HIV/AIDS programs is strengthening or weakening the fragile health systems of many developing countries. This article examines and assesses the evidence and proposes ways forward. DISCUSSION Considerably increased resources have been brought into countries for HIV/AIDS programs by major Global Health Initiatives. Among the positive impacts are the increased awareness of and priority given to public health by governments. In addition, services to people living with HIV/AIDS have rapidly expanded. In many countries infrastructure and laboratories have been strengthened, and in some, primary health care services have been improved. The effect of AIDS on the health work force has been lessened by the provision of antiretroviral treatment to HIV-infected health care workers, by training, and, to an extent, by task-shifting. However, there are reports of concerns, too - among them, a temporal association between increasing AIDS funding and stagnant reproductive health funding, and accusations that scarce personnel are siphoned off from other health care services by offers of better-paying jobs in HIV/AIDS programs. Unfortunately, there is limited hard evidence of these health system impacts. Because service delivery for AIDS has not yet reached a level that could conceivably be considered "as close to Universal Access as possible," countries and development partners must maintain the momentum of investment in HIV/AIDS programs. At the same time, it should be recognized that global action for health is even more underfunded than is the response to the HIV epidemic. The real issue is therefore not whether to fund AIDS or health systems, but how to increase funding for both. SUMMARY The evidence is mixed - mostly positive but some negative - as to the impact on health systems of the scaled-up responses to HIV/AIDS driven primarily by global health partnerships. Current scaled-up responses to HIV/AIDS must be maintained and strengthened. Instead of endless debate about the comparative advantages of vertical and horizontal approaches, partners should focus on the best ways for investments in response to HIV to also broadly strengthen the primary health care systems.
Collapse
Affiliation(s)
- Dongbao Yu
- HIV Department, World Health Organization, Avenue Appia, 1211 Geneva, Switzerland
| | - Yves Souteyrand
- HIV Department, World Health Organization, Avenue Appia, 1211 Geneva, Switzerland
| | - Mazuwa A Banda
- HIV Department, World Health Organization, Avenue Appia, 1211 Geneva, Switzerland
| | - Joan Kaufman
- AIDS Public Policy Project, John F. Kennedy School of Government, Harvard University, & Schneider Institutes for Health Policy, Heller School for Social Policy and Management, Brandeis University, 415 South Street MS 035, Waltham, MA 02454, USA
| | - Joseph H Perriëns
- HIV Department, World Health Organization, Avenue Appia, 1211 Geneva, Switzerland
| |
Collapse
|
9
|
dos Reis Serra CH, Mori Koono EE, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy brazilian volunteers: An open-label, randomized, single-dose, two-way crossover study. Clin Ther 2008; 30:902-8. [DOI: 10.1016/j.clinthera.2008.05.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2008] [Indexed: 10/21/2022]
|
10
|
Pan G, Elmquist WF. Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Mol Pharm 2007; 4:475-83. [PMID: 17388607 DOI: 10.1021/mp060083b] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Mitoxantrone (MXR) is a prototypical substrate for the ABCG2 (bcrp1) efflux transporter and is often used as a positive control in bcrp-mediated transport studies. This study examined processes involved in the cellular accumulation and directional transport of MXR using an in vitro wild-type (WT) and bcrp1-transfected (bcrp1) MDCKII cell model. Compared to 37 degrees C, incubation at 4 degrees C increased MXR accumulation in bcrp1 cells and unexpectedly decreased MXR accumulation in WT MDCKII cells. [3H]-MXR accumulation was concentration dependent in both WT and bcrp1 cells, exhibiting the characteristics of saturable active influx. At tracer concentrations, there was no difference in MXR directional flux between WT and bcrp1 MDCKII cell monolayers, and the A-to-B (apical-to-basolateral) flux was greater than the B-to-A flux in both cell types. However at higher concentration (20 microM), [3H]-MXR directional flux from A to B decreased and B to A increased, revealing the expected efflux process. Therefore, the orientation of the MXR directional flux process is concentration dependent and only at higher concentrations could the difference between WT and bcrp1 MDCKII cells be distinguished. Taken together, these data show that there is a saturable influx transport system on the apical membrane MDCKII cells that is responsible for the active influx of MXR. This is the first report of an active influx transport system for MXR. The expression of the putative MXR influx transporter in selected cell types could lead to misleading results in drug transport assays that screen for bcrp activity. Moreover, the downregulation of the influx transport system could be a heretofore unrecognized mechanism of MXR resistance in tumor cells.
Collapse
Affiliation(s)
- Guoyu Pan
- Department of Pharmaceutics, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota 55455, USA
| | | |
Collapse
|
11
|
Tantivess S, Walt G. Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand. COST EFFECTIVENESS AND RESOURCE ALLOCATION 2006; 4:21. [PMID: 17196110 PMCID: PMC1779364 DOI: 10.1186/1478-7547-4-21] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2006] [Accepted: 12/30/2006] [Indexed: 11/26/2022] Open
Abstract
Background: Much emphasis is put on providing evidence to assist policymakers in priority setting and investment decisions. Assessing the cost-effectiveness of interventions is one technique used by policymakers in their decisions around the allocation of scarce resources. However, even where such evidence is available, other considerations may also be taken into account, and even over-ride technical evidence. Antiretroviral therapy (ART) is the most effective intervention to reduce HIV-related morbidity and prolong mortality. However, treatment provision in the developing world has been hindered by the high costs of services and drugs, casting doubts on its cost-effectiveness. This paper looks at Thailand's publicly-funded antiretroviral initiative which was first introduced in 1992, and explores the extent to which cost-effectiveness evidence influenced policy. Methods: This article reviews the development of the national ART programme in Thailand between 1992 and 2004. It examines the roles of cost-effectiveness information in treatment policy decisions. Qualitative approaches including document analysis and interview of key informants were employed. Results: Two significant policy shifts have been observed in government-organised ART provision. In 1996, service-based therapy for a few was replaced by a research network to support clinical assessments of antiretroviral medication in public hospitals. This decision was taken after a domestic study illustrated the unaffordable fiscal burden and inefficient use of resources in provision of ART. The numbers of treatment recipients was maintained at 2,000 per year throughout the 1990s. It was not until 2001 that a new government pledged to extend the numbers receiving the service, as part of its commitment to universal coverage. Several elements played a role in this decision: new groups of dominant actors, drug price reductions, a pro-active civil society movement, lessons from experience on treatment benefits, and global treatment advocacy. Unlike previous policy discourse, human rights, ethics and equity notions were explicitly raised to support therapy extension. Conclusion: In the early decision, moving from a relatively limited ART service to a research network was clearly influenced by cost-effectiveness data. But in the 2001 decision to include ART in the universal coverage package, cost-effectiveness arguments were over-ruled by other considerations. Thai ART policy was shaped by many factors, and was not a simple rational process which relied on evidence.
Collapse
Affiliation(s)
- Sripen Tantivess
- International Health Policy Programme, Bureau of Policy and Strategy, Ministry of Public Health, Nonthaburi, Thailand
| | - Gill Walt
- London School of Hygiene and Tropical Medicine, London, UK
| |
Collapse
|
12
|
Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India. Clin Infect Dis 2006; 44:295-300. [PMID: 17173234 DOI: 10.1086/510491] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2006] [Accepted: 09/19/2006] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND The nutritional and body shape response after the initiation of highly active antiretroviral therapy (HAART) in resource-limited environments has not been documented. In this environment, nutritional compromise is a common complication of human immunodeficiency virus (HIV) infection. METHODS We conducted a prospective study of 190 HIV-infected patients who initiated a nevirapine-based HAART regimen. CD4+ T cell count, body weight, body mass index, anthropometry, and bioelectrical impedance data were collected prior to initiation of therapy and after 6 months of therapy. RESULTS The mean age of participants was 35 years, 85% of participants were male, and 59% received stavudine as 1 of the nucleosides in their initial HAART regimen. The members of the cohort were malnourished before the initiation of therapy and had a mean body mass index of 20.1 (calculated as weight in kilograms divided by the square of height in meters). Overall, body weight increased a mean of 2.8 kg (range, -12.5 to 22.5 kg), and CD4+ T cell counts increased by a mean of 140 cells/mm3. Patients were stratified into those who lost weight (loss of >1 kg, 22%; n=41), those whose weight remained stable (19%; n=37), and those who gained weight (gain of >1 kg, 59%; n=112). Patients in all groups retained body shape symmetry and experienced no change in waist-to-hip ratio or regional body shape by anthropometry. CONCLUSIONS The group that lost weight and the group whose weight remained stable experienced significant CD4+ T cell count increases at 6 months. Although the majority of HIV-infected patients who received nevirapine-based HAART gained weight, there were participants who lost weight despite initiating their first HAART therapy.
Collapse
Affiliation(s)
- Suneeta Saghayam
- YR Gaitonde Centre for AIDS Research and Education, Chennai, 600 113, India.
| | | | | | | | | | | |
Collapse
|
13
|
|
14
|
|